blood culture News
-
Kurin, Inc. Announces Agreement with AllSpire Health GPO to Impact Contaminated Blood Cultures
Kurin. Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture sets, announced the signing of a recent agreement with AllSpire Health GPO. The agreement is sole source and is for three years. “AllSpire Health GPO and Kurin are committed to patient safety by providing innovative solutions designed to address a common source of contaminated blood cultures and in doing ...
By Kurin, Inc.
-
Kurin, Inc. Announces Launch of Its Proprietary Push-button Needle System
Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced that they have commenced the commercial launch of their push-button needle, to be used as part of Kurin blood culture sets. The Advance Safety Needle System was tested in 2021 and is now being sold into accounts using Kurin. “We are proud to commercialize the Advance Safety Needle, as there ...
By Kurin, Inc.
-
Kurin, Inc. announces UK clinical study results showing significant decrease in blood culture contaminations with the Kurin Lock™
Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today a new clinical study supporting the efficacy of their blood culture collection product. Authors from Guy’s and St. Thomas’ NHS Foundation Trust, a prestigious London-based hospital, presented their data at the recent Infection Prevention Society conference in ...
By Kurin, Inc.
-
Kurin, Inc. Announces Removal of Magnolia Patent Infringement Lawsuit Trial Date
Kurin Inc., the inventor and manufacturer of Kurin® blood culture collection sets, announced that the U.S. District Court in Delaware has removed the trial date from the docket in the patent-infringement lawsuit brought against Kurin by Magnolia Medical. The Court indicated that, if necessary, it will provide a trial date after it decides motions for summary judgment. This delay followed ...
By Kurin, Inc.
-
Kurin, Inc. Named to Inc.’s Inaugural Best in Business List in the Prosperous and Thriving Category
Kurin, Inc. has been named to Inc.’s inaugural Best in Business list in the Prosperous and Thriving category. Inc. created the Best in Business Awards to honor companies that have gone above and beyond to make a positive difference. The list, which can be found in the Winter issue of Inc. (on newsstands December 29, 2020), recognizes small- and medium-size privately held American ...
By Kurin, Inc.
-
Kurin, Inc. announces peer-reviewed publication on Kurin® efficacy from Central Texas Veterans Health Care System
Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that the Central Texas VA Health Care System in Temple, TX, published their findings comparing results of two devices: Kurin and Steripath® (Magnolia Medical Technologies, Inc.) in the online edition of the Journal of Emergency Nursing. This is the first peer-reviewed ...
By Kurin, Inc.
-
New performance data for Accelerate Arc to be presented April 25 at ECCMID
Today we announced the release of new performance data across two studies for the Accelerate Arc module and BC kit at the 32nd European Congress for Clinical Microbiology and Infectious Diseases (ECCMID) located in Lisbon, Portugal 23-26 April 2022. Two posters featuring performance of the Accelerate Arc System will be presented on Monday April 25th, 12:00- 13:00 hr, Pavilion 3 of the Feira ...
-
Accelerate Diagnostics completes IVD registration of the Accelerate Arc system with U.S. FDA
Designed for labs with MALDI platforms, the Accelerate Arc Module and BC kit is a novel application of inline centrifugation and automated sample prep techniques, which together with the blood culture (BC) kit, provides a suspension of cleaned microbial cells for direct transfer to a MALDI spotting plate. Accelerate Arc system now available as a registered IVD Today we announced the completed ...
-
Magnolia Medical, MHA Solutions, and Healthcare Providers Insurance Company Enter into an Exclusive, Endorsed Agreement for the Steripath Initial Specimen Diversion Device
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 announced today that it has entered into an endorsed company agreement with MHA Solutions, a subsidiary of the Mississippi Hospital Association (MHA), and Healthcare Providers Insurance (HPIC), a reciprocal insurer that ...
-
Magnolia Medical Announces Expansion of Its Extensive Clinical Evidence Library with Six Steripath® ISDD® Studies in 2021 Demonstrating Zero or Near-Zero False Positive Sepsis Test Results
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 today announced that six studies, reporting zero or near-zero blood culture contamination rates and up to a 31% reduction in vancomycin days of therapy (DOT) using Steripath, were submitted, accepted and published in ...
-
Kurin, Inc. announces results on Kurin efficacy from Oishei Children`s Hospital with zero blood culture
Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that Oishei Children’s Hospital, a member of Kaleida Health, in Buffalo, NY, presented their findings on their use of Kurin at the recent Association for Professionals in Infection Control conference. This is the first study of Kurin, a passive low-volume blood culture ...
By Kurin, Inc.
-
Members of Congress Urge CMS to Take Action to Reduce Preventable False-Positive Diagnostic Test Results for Sepsis
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing1, commended U.S. Representatives Mike Levin (D-CA), Gus Bilirakis (R-FL), and eight of their colleagues for sending a joint, bipartisan letter urging the Centers for Medicare and Medicaid Services (CMS), an agency within ...
-
Accelerate Diagnostics Announces Launch Of Accelerate Arc Module and BC Kit
The Accelerate Arc System cuts hours of wait time and numerous manual steps to deliver Identification (ID) results Unlocks rapid microbial ID from positive blood cultures for the large installed base of MALDI system users Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an in-vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis, ...
-
Vela Diagnostics Buys Great Basin Scientific
Adds 6 FDA Approved Products on a Medium Multiplexing Platform and Microbiology Know-how Enabling our Customers to Benefit from a New Sample-to-Result Solution Cost-Efficiently in Near Patient Care Setting; adds a Manufacturing and R&D site in Salt Lake City, UT, United States. Vela Diagnostics signed an agreement to acquire Great Basin Scientific’s assets and will take over their site ...
-
Specific Diagnostics Commences US Clinical Trials for FDA 510(k) Clearance of its Reveal Rapid AST System
Specific Diagnostics announces today the commencement of its US clinical studies for the Reveal Rapid AST System for blood infection. Trials will entail 3 months of data collection followed by submission for FDA consideration of 510(k) clearance of the Reveal test. In Europe, where the Reveal is launched under CE-IVD registration, 11 studies across France and England comprising over 1,400 ...
-
Magnolia Medical Appoints Industry Veteran, Joseph Bishop, as the Senior Vice President of Operations and Product Development
Magnolia Medical Technologies, Inc., inventors of Steripath, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 today announced the addition of Joseph Bishop to the executive leadership team as Senior Vice President of Operations and Product Development. Mr. Bishop brings extensive and diverse medical device experience to Magnolia ...
-
Specific Diagnostics Announces the Formation of its US Commercial Team and Introduction of the Reveal Rapid AST System to the US Market
Specific Diagnostics today announced formation of its US commercial sales, service, support and marketing teams in anticipation of the launch of the Reveal Rapid AST System for blood infection samples. Following 11 studies across France and England comprising over 1,400 clinical positive blood culture samples, yielding overall accuracy of 97.8%, and in tandem with the commencement of clinical and ...
-
Magnolia Medical Further Strengthens Executive Management Team with the Addition of Silicon Valley Financial Leader, Patrick O’Malley, as Chief Financial Officer
Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing,1 today announced the expansion of its senior leadership team with the addition of Patrick O’Malley as Chief Financial Officer. Mr. O’Malley is a seasoned public company executive bringing over three decades ...
-
Specific Diagnostics Announces the Creation of a European Warehouse and Servicing Center
Specific Diagnostics today announces the opening of its European warehouse and servicing center in Amsterdam, Netherlands, to support its growing European operations. Working with global integrated logistics leader Crane Worldwide Logistics, Specific and its European subsidiary Specific Diagnostics Europe, Ltd., will warehouse Reveal® instruments and consumables in the Amsterdam facility. The ...
-
Qvella Appoints Richard Brock as VP of Global Marketing and Signals Start of Commercialization
Qvella, a diagnostics company that aims to reduce the time to results in the diagnosis of infections, today announced that it has appointed Richard Brock as VP of Global Marketing. In this role, he will lead the imminent commercialization of Qvella’s FAST-Prep™ product for Positive Blood Culture (PBC) processing. He will be responsible for the company’s go-to-market and product ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you